Why metabolic syndrome criteria have not made prime time: A view from the clinic

International Journal of Obesity

Volumn 32, Issue , 2008, Pages S30-S34

  Sattar, N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Framingham risk score; Hypertension; Lipids

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; CONFIDENCE INTERVAL; DIABETES MELLITUS; ETHNICITY; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MATHEMATICAL MODEL; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; RISK ASSESSMENT;

EID: 43449105916     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.33     Document Type: Article

References (17)

1. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.
2. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in theWest of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–362.
3. Hanley AJ, Karter AJ, Williams K, Festa A, D’Agostino Jr RB, Wagenknecht LE et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112: 3713–3721.
4. Ellison TL, Elliott R, Moyes SA. HbA1c screening for undiagnosed diabetes in New Zealand. Diabetes Metab Res Rev 2005; 21: 65–70.
5. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.
6. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte OP, et al., Euro Heart Survey Investigators. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27: 2969–2974.
7. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385–390.
8. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676–2681 [Published erratum appears in Diabetes Care 2005; 28: 238].
9. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 2644–2650.
10. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878–882.
11. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141.
12. JBS2. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v1–v52.
13. Sattar N. The metabolic syndrome: should current criteria influence clinical practice? Curr Opin Lipidol 2006; 17: 404–411.
14. Sniderman A, Williams K, Haffner S, Sattar N. Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. Atheroscler Suppl. 2004; 5: 19–24.
15. Williams K, Sniderman AD, Sattar N, D’Agostino Jr R, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108: 2312–2316.
16. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631–2639.
17. Lean M, Gruer L, Alberti G, Sattar N. ABC of obesity. ObesityFcan we turn the tide? BMJ 2006; 333: 1261–1264.